2nd ADC Process Development Summit
When:
Tuesday, Sep 17, 2024 8:00a -
Thursday, Sep 19, 2024 4:45p
Tuesday, Sep 17, 2024 8:00a -
Thursday, Sep 19, 2024 4:45p
Where:
The Westin Boston Seaport District
425 Summer Street
Boston, Massachusetts 02210
Admission:
$2899.00 - $4997.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2471245-3?pid=5248
With cutting-edge strategies and industry insights, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield, optimize purification, and streamline production to meet regulatory standards all whilst minimizing costs and timelines.
Join AstraZeneca, Bristol Myers Squibb, Pfizer and a community of industry experts in process development, conjugation, purification, control, CMC, and engineering. With a focused discussion on process development challenges, innovative solutions and practical takeaways, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process.
This Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF, implement rigorous control strategies for superior drug substance quality, develop scalable processes to cut unit operations, accelerate production timelines, and navigate regulatory landscapes with ease.
Don’t miss this Summit, where innovation meets implementation, ensuring your ADC process development reaches its optimal efficacy and efficiency!
URLs:
Brochure: https://go.evvnt.com/2471245-0?pid=5248
Tickets: https://go.evvnt.com/2471245-2?pid=5248
Prices:
Drug Developer Conference + Workshop Day Ticket: USD 4097.00,
Drug Developer Conference Only: USD 2899.00,
Solution Provider Conference + Workshop Day: USD 4997.00,
Solution Provider Conference Only: USD 3599.00
Speakers: Benjamin Hutchins, Vice President, Technical Operations, Mythic Therapeutics, Brandon Coyle, Senior Research Scientist II, Gilead Sciences, Cuihua (Tracy) Zhu, Associate Director, Pheon Therapeutics Ltd, Dharti Kothari, Senior Scientist - Downstream Process Development, Independent, Engin Ayturk, Senior Director, CMC Bioconjugation, Process Development and Manufacturing, Exelixis Inc., Eric Lacoste, Head of ADC Conjugation Development/Global CMC Development, Sanofi, Hong Shen, Principal Scientist, Johnson and Johnson Services, Inc, Hui Wei, Director - Chair, Biologics Specification Committee, Analytical Chemistry Manufacturing and Controls Strategy Lead, Bristol Myers Squibb, Jianxin Guo, Director - Regulatory Chemistry Manufacturing and Controls Biotechnology, Eli Lilly and Co., Joshua Hunter Director - Conjugation Process Development, Pfizer, Linan Ha, Director, Regulatory Affairs, CMC, AstraZeneca, Nimish Gupta, Senior Staff Engineer, Regeneron Pharmaceuticals Inc, Prakash Manikwar, Assocaite Director, AstraZeneca, Robert Hughes, Senior Director - Pharmaceutical Sciences, Cidara Therapeutics Inc., Sarah Owen, Senior Scientist, Seagen, Shiyue Zhou, Principal Research Scientist I, Abbvie, Vineet Kumar, Senior Director - Development, DP manufacturing and Chemistry, Manufacturing, and Controls Project Management, Exelixis Inc.
-
Sponsored -
SponsoredAffordable Spanish Classes in Boston (in-person and online courses) | BASE
Monday, Jan 13, 2025 goes until 03/15
Boston Area Spanish Exchange (BASE)
-
Sponsored
